The ISN was deeply saddened to learn of the death of Professor Rashad Barsoum.
Professor Barsoum served the ISN in several roles, including as ISN secretary-general from 1999-2005. He was a pillar of the ISN’s most renowned programs, directing both the Fellowship and Sister Renal Centers Programs in the early 2000s.
Kidney International Publishes Results From the ISN Emerging Leaders' Survey Exploring Barriers to Accessing Essential Medicines for People With CKD in Lower Income Countries
Discover the results of the first ISN ELP cohort's web-based multinational survey of healthcare workers on access and barriers to essential medicines in low and low to middle-income countries for people with CKD.
"It's a Patients' Platform," Dr. Jeyakumar Meyyappan on Why Winning the 2022 ISN Community Film Event Beats His Other Awards
In an ISN video interview, Dr. Meyyappan said he was inspired by Mr. Saad Ahmad Khan, who remains cheerful despite waiting for over a decade for a kidney transplant. Dr. Meyyappan encourages others to identify kidney health issues in their region and share a related story from one of their patients with the ISN Community Film Event.
Executive Summary of the KDIGO 2022 Diabetes Management in CKD Guideline: An Update Based on Rapidly Emerging New Evidence
This guideline update was developed through a stringent review process of relevant studies and an evaluation of the quality of the evidence according to the “Grading of Recommendations Assessment, Development and Evaluation” (GRADE) approach.
Limitations of the evidence are discussed, and areas that need additional research are presented.
Efficacy, Safety, and Tolerability of Oral Furosemide Among Patients Receiving Hemodialysis: A Pilot Study
This study evaluates furosemide's efficacy, safety, and tolerability in patients with hemodialysis-dependent kidney failure. Researchers found that furosemide was generally safe and well tolerated. However, only one-third of participants achieved efficacy five weeks later, making the clinical importance of the efficacy findings uncertain.